ABSTRACT

Background: Disease-specific factors that predispose patients to diverse cardiac diseases in systemic lupus erythematosus (SLE) have been established. The aim of this study was to identify risk factors for cardiac involvement in patients with SLE drawn from the Korean Lupus Network (KORNET) registry.

Methods: A total of 437 patients with SLE recruited from the KORNET registry were included in the analysis. The Cox proportional hazard model was used to identify risk factors for the development of cardiac involvement during the follow-up period. The hazard ratios for risk factors of cardiac involvement were assessed using Kaplan-Meier curves and log-rank test.

Results: Of 437 patients with SLE, 12 patients (2.7%) developed new cardiac involvement during a median follow-up period of 47.6 months. Frequencies in men and in patients with anti-Sm antibody, anti-Ro antibody, and at least one Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SDI) score in patients with cardiac involvement were higher, compared to those without cardiac involvement (P < 0.001, P = 0.026, P = 0.015, and P < 0.001, respectively). Men gender, older age, anti-Sm antibody, SDI, and corticosteroid dosage were potent predictors for cardiac involvement. Men, anti-Sm antibody positivity, and SDI ≥ 1 increased incidence rates of cardiac involvement for (P < 0.001, P = 0.036, and P < 0.001, respectively).

Conclusion: The results of this study reveal that SLE-related factors such as anti-Sm antibody, SDI, and corticosteroid dosage at baseline are risk factors for cardiac involvement in SLE.

Keywords: Systemic Lupus Erythematosus; Cardiovascular Disease; Autoimmunity; Steroid
heterogeneous pathogenic mechanisms.\(^1,2\) The mortality rate of patients with lupus is estimated to be about three fold higher than that of the age- and gender-matched general population.\(^3\) Cardiovascular disease (CVD) is one of the leading causes of increasing morbidity and mortality in patients with SLE, together with infection and adverse effects due to therapeutic strategies.\(^4,7\) Earlier studies observed that the prevalence of clinical cardiac diseases in SLE ranged from 8% to 10% according to study population and CVD outcomes.\(^8,9\) In particular, epidemiological evidence suggests that patients with SLE are about 9 to 50 fold more likely to experience increased risk of CVD including myocardial infarction and angina pectoris, compared to the general population.\(^10,11\)

The risk of development of CVD in SLE is related not only to traditional risk factors such as older age, hypertension, dyslipidemia, and diabetes mellitus, but also to disease-specific factors such as disease activity, autoantibodies, major organ damage, and treatment modality.\(^10,12\) However, traditional risk factors, such as those proposed in the general population, do not fully explain the outcomes of CVD in SLE. Furthermore, the relationships between disease-specific factors and CVD outcomes vary depending on the characteristics of the study population, including population size, origin and ethnicity. One epidemiologic study conducted using the Korean National Health Insurance Service database revealed that SLE itself was an independent risk factor for CVD in Korean population.\(^13\) However, few data about traditional and disease-related risk factors for cardiac involvements including vascular and non-vascular events in Korean patients with SLE are available. Therefore, the aim of this study was to investigate traditional and lupus-related risk factors of cardiac involvement in patients with SLE recruited from a nationwide prospective multicenter-based registry.

**METHODS**

**Study population**

Six university-based medical centers participated in the Korean Lupus Network (KORNET) registry, which was a prospective study, from January 2014 to December 2018. All subjects were recruited by rheumatologists at the outpatient clinics of each center and fulfilled the 1982 revised and 1997 updated American College of Rheumatology classification criteria for SLE.\(^14,15\) Four hundred thirty-seven patients who did not have any cardiac involvement were eligible for inclusion in this study.

**Collection of clinical information**

This study used clinical data collected from baseline to the latest follow-up. Clinical information at baseline included age (years), gender, disease duration (months), smoking status (non-current smoker and current smoker), alcohol intake (current alcoholic and non-current alcoholic), systolic blood pressure (SBP, mmHg), diastolic blood pressure (DBP, mmHg), and body mass index (BMI, kg/m\(^2\)). BMI was classified into two groups: normal (< 23.0) and overweight and obese (≥ 23.0) according to criteria proposed by the International Obesity Task Force for East Asian adults.\(^16\)

Comorbidities were identified through reviews of medical records and interviews with each subject and included hypertension, hyperlipidemia, diabetes mellitus, and renal disorders. Hypertension is defined when the condition was previously diagnosed and the patient is currently taking anti-hypertensive medications or has blood pressure 140/90 mmHg or above at the time of enrollment. Patients taking anti-hyperlipidemic drugs due...
to hypercholesterolemia or hypertriglyceridemia or with fasting total cholesterol above 240 mg/dL, low-density lipoprotein cholesterol above 130 mg/dL, or triglycerides above 150 mg/dL were considered to have hyperlipemia. Diabetes mellitus is defined when previously diagnosed and the patient is currently taking anti-diabetic medications.

**Assessments of SLE-related measures**

Inflammatory and immunologic markers at baseline included erythrocyte sedimentation rate (mm/hr), C-reactive protein (mg/dL), complement 3 (mg/mL), complement 4 (mg/mL), and positivity for autoantibodies such as anti-dsDNA antibody, anti-Sm antibody, anti-Ro antibody, anti-La antibody, anti-RNP antibody, lupus anticoagulant, anti-cardiolipin antibody, and anti-β2GPI antibody. Disease activity was measured using the safety of estrogen in lupus erythematosus national assessment (SELENA)-SLE disease activity index (SLEDAI). Assessments for SLE-related organ damage were performed using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SDI). Patients diagnosed with lupus nephritis or with abnormality in the urinalysis such as proteinuria and hematuria provided by the definition of SELENA-SLEDAI were regarded as having renal involvement.

**Determination of cardiac involvement in SLE**

New onset cardiac events were identified using data from baseline to the latest follow-up. In this study we identified vascular cardiac events such as angina pectoris and myocardial infarction, and other non-vascular cardiac involvement including cardiomyopathy, valvular heart disease, and pericarditis. At the time of registry enrollment, patients without a history of cardiac diseases as described above were included. The onset of vascular or heart events such as stroke, congestive heart failure, peripheral vascular disease, and venous thrombus were excluded during the follow-up period.

**Statistical analysis**

Data were presented as median (interquartile range [IQR]) for quantitative (numeric) variables and numbers (%) for qualitative (categorical) variables. Kolmogorov-Smirnov analysis revealed that the data did not show a normal distribution. Therefore, non-parametric methods were used for statistical analysis. Comparisons of clinical variables between patients with and without cardiac manifestations were performed by χ² tests, t-tests, or Fisher’s exact tests for qualitative variables and Mann-Whitney U tests for quantitative variables, if available.

We used the Cox proportional hazard regression model to determine whether variables at baseline influence the development of CVD. In model 1, variables that differed significantly between patients with and without CVD were used as independent variables for crude analysis. Model 2 and model 3 were calculated after adjusting for additional confounding variables such as traditional risk factors, disease-specific activity indexes, and medications for adjusted analysis. In model 2, traditional risk factors such as smoking, BMI, hypertension and hyperlipidemia, diabetes mellitus and renal involvement were added to model 1. In model 3, disease-specific activity indexes and medications such as SELENA-SLEDAI, anti-dsDNA antibody, complement 3, complement 4, corticosteroid dose, hydroxychloroquine dose were added to model 2.

Cumulative incidence rates of CVD by gender, anti-Sm antibody, and SDI were estimated by the Kaplan-Meier method and the log-rank tests were used to compare between two incidence curves. The proportional hazards assumption was checked by log minus log plot.
The curves by group variables were not cross and maintain parallel. Therefore, the ratio of the hazards for any two individuals is constant over time. The data were described as hazard ratio (HR) with 95% confidence interval (CI) for CVD. Cumulative incidence rates of CVD using candidates such as gender, anti-Sm antibody, and SDI were estimated by the Kaplan-Meier method. The data were described as incidence rate with 95% CI for each candidate. P values < 0.05 were considered to indicate statistical significance. The statistical analyses were performed using IBM SPSS ver. 19.0 (IBM Corp., Armonk, NY, USA).

Ethics statement
At the time of enrollment in the KORNET registry, all subjects gave written informed consent for inclusion in this study. This study was approved by the Institutional Review Board of Daegu Catholic University Medical Center (CR-19-097). This study was performed according to the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

RESULTS

Baseline characteristics of the study population
A total of 437 patients (n = 409, 93.6%, women) were included in our analysis (Table 1). The median follow-up period of these patients was 47.6 months (IQR, 45.0–49.2). Traditional risk factors related with cardiac involvement such as smoking status, alcoholic intake, SBP, DBP, and BMI, and comorbidities including hypertension, hyperlipidemia, diabetic mellitus, and renal involvement are shown in Table 1. In addition, SLE-specific disease activity or damage indexes including SELENA-SLEDAI, SDI, complement 3, complement 4, autoantibodies, and current medications at the time of enrollment were also identified.

Comparisons of baseline variables between patients with and without cardiac involvement
Among 437 patients, cardiac involvement in 12 patients (2.7%) newly developed during the follow-up period (Table 1). Cardiac involvement included angina pectoris (n = 3), myocardial infarction (n = 3), cardiomyopathy (n = 2), valvular heart disease (n = 2), and pericarditis (n = 2). Men patients had more frequent cardiac involvement than women patients (P < 0.001). There were no differences between patients with cardiac involvement and without cardiac involvement in age, follow-up duration, disease duration, smoking status, alcoholic intake, SBP, DBP, BMI, hypertension, hyperlipidemia, diabetic mellitus, or renal involvement at baseline (P > 0.05 for all). Considering SLE-specific parameters, patients with cardiac involvement showed higher SDI, more frequent anti-Sm antibody, and less frequent anti-Ro antibody (P < 0.001, P = 0.026, and P = 0.015, respectively), but there were no differences in other parameters.

Determination of risk factors related to cardiac involvement
The variables associated with cardiac involvement were determined using univariate analysis with Kaplan-Meier survival analysis (Table 2). The result showed that men, higher SDI, positive Sm antibody, and negative Ro antibody was found to be associated with cardiac involvement (HR, 14.060, P < 0.001; HR, 9.610, P = 0.001; HR, 3.170, P = 0.047, and HR, 0.250, P = 0.037, respectively). Cox proportional hazard model analysis by model 1 demonstrated that men gender, anti-Sm antibody, and higher SDI at baseline were positively associated with increased risk of cardiac involvement (HR, 8.103, P = 0.002; HR, 6.211,
Cardiac Involvement in Systemic Lupus Erythematosus

Table 1. Comparison of baseline characteristics according to cardiac involvement

| Variables                        | Total (n = 437) | Cardiac involvement | P value |
|----------------------------------|-----------------|---------------------|---------|
|                                  | Absence (n = 425) | Presence (n = 12)   |         |
| Gender, women                    | 409 (93.6)      | 402 (94.6)          | 0.599   |
| Age, yr                          | 44.0 (36.0–52.0) | 44.0 (36.0–51.0)    | 0.222   |
| Disease duration, mon            | 92.0 (39.0–167.0) | 91.0 (39.0–166.5)   | 0.599   |
| Traditional risk factors         |                 |                     |         |
| Current smoker                   | 46 (10.5)       | 45 (10.6)           | 1.000   |
| Current alcoholic                | 118 (27.0)      | 115 (27.1)          | 1.000   |
| Systolic blood pressure, mmHg    | 118.0 (110.0–128.0) | 118.0 (110.0–128.0) | 0.598   |
| Diastolic blood pressure, mmHg   | 71.0 (66.0–80.0) | 71.0 (66.0–80.0)    | 0.314   |
| BMI, kg/m²                       |                 |                     | 0.480   |
| Normal, < 23.0                   | 296 (67.7)      | 289 (68.0)          | 0.796   |
| Overweight and obese, ≥ 23.0     | 141 (32.3)      | 136 (32.0)          | 0.449   |
| Hypertension                     | 87 (19.9)       | 84 (19.8)           | 0.713   |
| Hyperlipidemia                   | 54 (12.4)       | 52 (12.5)           | 1.000   |
| Diabetes mellitus                | 36 (8.2)        | 33 (7.8)            | 0.067   |
| Renal involvement                | 117 (26.8)      | 111 (26.1)          | 0.031   |
| Erythrocyte sediment rate, mm/hr | 20.0 (10.0–33.1) | 20.0 (10.0–33.2)   |         |
| C-reactive protein, mg/dL        | 0.09 (0.05–0.30) | 0.09 (0.05–0.30)   | 0.998   |
| Disease-specific parameters      |                 |                     |         |
| SELENA-SLEDAI                    | 3.0 (2.0–6.0)   | 3.0 (2.0–6.0)       | 0.338   |
| SDI, ≥ 1                         | 100 (22.9)      | 91 (21.4)           | < 0.001 |
| Complement 3, mg/mL              | 80.4 (66.0–96.0) | 80.1 (66.0–95.9)    | 0.834   |
| Complement 4, mg/mL              | 15.2 (10.5–20.5) | 15.0 (10.5–20.3)   | 0.355   |
| Anti-Sm antibody                 | 93 (21.5)       | 87 (20.7)           | 0.026   |
| Anti-dsDNA antibody              | 227 (52.1)      | 219 (51.7)          | 0.305   |
| Anti-Ro antibody                 | 261 (60.3)      | 258 (61.3)          | 0.015   |
| Anti-La antibody                 | 97 (22.4)       | 97 (23.0)           | 0.077   |
| Anti-RNP antibody                | 157 (36.6)      | 151 (36.2)          | 0.369   |
| Anti-cardiolipin antibody        | 36 (8.5)        | 36 (8.8)            | 0.611   |
| Anti–J2GPI antibody              | 25 (5.9)        | 25 (8.1)            | 1.000   |
| Lupus anticoagulant              | 44 (10.3)       | 43 (10.4)           | 1.000   |
| Current medications              |                 |                     |         |
| Methotrexate                     | 27 (6.2)        | 27 (6.4)            | 1.000   |
| Hydroxychloroquine               | 403 (92.2)      | 391 (92.0)          | 0.811   |
| Tacrolimus                       | 22 (6.8)        | 19 (6.3)            | 0.082   |
| Azathioprine                     | 74 (16.9)       | 71 (16.7)           | 0.436   |
| Mycophenolate mofetil            | 71 (16.2)       | 69 (16.2)           | 1.000   |
| Corticosteroid                   | 357 (81.7)      | 345 (81.2)          | 0.135   |
| Corticosteroid, mg/day           | 5.0 (3.7–7.5)   | 5.0 (3.7–7.5)       | 0.609   |
| Anti-hypertension drug           | 30 (6.9)        | 29 (6.8)            | 0.838   |
| Anti-lipid drug                  | 25 (5.7)        | 26 (2.6)            | 0.693   |

Data was described as median (interquartile range) or number (%).
BMI = body mass index, SELENA-SLEDAI = Safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index, SDI = Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index.

*There are missing data for smoker (n = 68), alcoholic (n = 67), complement 3 (n = 1), complement 4 (n = 1), anti-Sm antibody (n = 5), anti-dsDNA antibody (n = 1), anti-Ro antibody (n = 4), anti-La antibody (n = 4), anti-RNP antibody (n = 8), anti-cardiolipin antibody (n = 14), anti–J2GPI antibody (n = 14), and lupus anticoagulant (n = 10).

P = 0.010; HR, 5.238, P = 0.021, respectively (Table 3), whereas anti-Ro antibody was negatively associated with cardiac involvement (HR, 0.182, P = 0.024). Model 2 showed similar results after adjusting for traditional risk factors such as smoking, BMI, hypertension, hyperlipidemia, diabetes mellitus, and renal involvement: gender, anti-Sm antibody, and SDI were risk factors for cardiac involvement (HR, 7.898, P = 0.012; HR, 10.219, P = 0.006; HR, 4.966, P = 0.038, respectively), whereas anti-Ro antibody was negatively associated with cardiac involvement (HR, 0.181, P = 0.035). After the addition of disease-specific indexes...
and medications as risk factors, analysis using model 3 showed that gender, age, anti-Sm antibody, SDI, and median daily dosage of corticosteroid at baseline were predictive risk factors for the development of cardiac involvement (HR, 2.899, \(P = 0.003\); HR, 1.006, \(P = 0.039\); HR, 2.132, \(P = 0.008\); HR, 1.068, \(P = 0.042\); HR, 1.112, \(P = 0.047\), respectively). Disease activity markers including SELENA-SLEDAI, complement 3, and complement 4 were not predictive of cardiac involvement.

### Table 2. Determination for variables associated with cardiac involvement

| Variables | HR | 95% CI for HR | \(P\) value |
|-----------|----|---------------|-------------|
| Gender, women | 14.060 | 4.271–46.259 | < 0.001 |
| Age, yr | 1.020 | 0.974–1.076 | 0.348 |
| Disease duration, mon | 1.000 | 0.995–1.007 | 0.794 |

#### Traditional risk factors

- Current smoker, ref: none 0.710 (0.091–5.576) \(P = 0.747\)
- Current alcoholic, ref: none 1.040 (0.273–3.943) \(P = 0.956\)
- Systolic blood pressure, mmHg 1.000 (0.961–1.030) \(P = 0.788\)
- Diastolic blood pressure, mmHg 0.990 (0.943–1.039) \(P = 0.681\)
- BMI, kg/m², ref: normal 1.450 (0.457–4.575) \(P = 0.530\)
- Hypertension, ref: absence 1.040 (0.277–3.887) \(P = 0.957\)
- Hyperlipidemia, ref: absence 0.660 (0.085–5.146) \(P = 0.691\)
- Diabetes mellitus, ref: absence 3.160 (0.827–12.047) \(P = 0.047\)
- Renal involvement, ref: absence 1.880 (0.588–5.987) \(P = 0.288\)
- Erythrocyte sediment rate, mm/hr 0.990 (0.949–1.027) \(P = 0.531\)
- C-reactive protein, mg/dL 0.840 (0.346–2.037) \(P = 0.698\)

#### Disease-specific parameters

- SELENA-SLEDAI 0.990 (0.869–1.123) \(P = 0.856\)
- SDI, ref: SDI = 0 9.610 (2.599–35.527) \(P = 0.001\)
- Complement 3, mg/mL 0.990 (0.966–1.023) \(P = 0.698\)
- Complement 4, mg/mL 1.010 (0.949–1.076) \(P = 0.741\)
- Anti-Sm antibody, ref: negative 3.170 (1.016–9.910) \(P = 0.047\)
- Anti-dsDNA antibody, ref: negative 1.960 (0.589–6.509) \(P = 0.273\)
- Anti-Ro antibody, ref: negative 0.250 (0.067–0.921) \(P = 0.037\)
- Anti-La antibody, ref: negative 0.030 (0.000–10.841) \(P = 0.249\)
- Anti-RNP antibody, ref: negative 1.310 (0.416–4.102) \(P = 0.646\)
- Lupus anticoagulant, ref: negative 0.680 (0.086–5.331) \(P = 0.712\)

BMI = body mass index, SELENA-SLEDAI = safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index, SDI = Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index, HR = hazard ratio, CI = confidence interval.

### Table 3. Cox proportional hazard model of risk factors for cardiac involvement according to baseline variables

| Variables | Model 1 | | | Model 2 | | | Model 3 | | |
|-----------|---------|---|---|---------|---|---|---------|---|---|
| Gender, ref: women | 8.103 | 2.124–30.909 | 0.002 | 7.898 | 1.574–39.639 | 0.012 | 21.683 | 2.899–162.196 | 0.003 |
| Age, yr | 1.024 | 0.969–1.081 | 0.402 | 1.043 | 0.978–1.112 | 0.199 | 1.124 | 1.006–1.256 | 0.039 |
| Anti-Sm antibody, ref: negative | 6.211 | 1.545–24.974 | 0.010 | 10.219 | 1.931–54.090 | 0.006 | 17.746 | 2.132–147.675 | 0.008 |
| Anti-Ro antibody, ref: negative | 0.182 | 0.041–0.796 | 0.024 | 0.181 | 0.037–0.889 | 0.035 | 0.367 | 0.065–2.079 | 0.257 |
| SDI, ref: SDI = 0 | 5.238 | 1.280–21.426 | 0.021 | 4.966 | 1.091–22.602 | 0.038 | 6.444 | 1.068–38.873 | 0.042 |
| Smoking, ref: non-smoking | 1.104 | 0.115–10.622 | 0.932 | 0.329 | 0.016–6.657 | 0.469 |
| BMI, ref: normal | 0.639 | 0.142–2.877 | 0.560 | 0.342 | 0.047–2.507 | 0.291 |
| Hypertension, ref: absence | 1.538 | 0.314–7.540 | 0.595 | 1.487 | 0.211–10.495 | 0.691 |
| Hyperlipidemia, ref: absence | 0.476 | 0.050–4.497 | 0.517 | 0.171 | 0.007–4.364 | 0.285 |
| Diabetes mellitus, ref: absence | 2.473 | 0.487–12.547 | 0.275 | 1.492 | 0.214–10.456 | 0.686 |
| Renal involvement, ref: absence | 2.304 | 0.607–8.744 | 0.220 | 2.492 | 0.413–15.046 | 0.319 |
| SELENA-SLEDAI | 0.959 | 0.780–1.178 | 0.687 |
| Anti-dsDNA antibody, ref: negative | 6.123 | 0.560–66.908 | 0.137 |
| Complement 3, mg/mL | 1.004 | 0.951–1.060 | 0.882 |
| Complement 4, mg/mL | 1.006 | 0.904–1.120 | 0.908 |
| Corticosteroid dose, mg/day | 1.112 | 1.001–1.234 | 0.047 |
| Hydroxychloroquine dose, mg/day | 0.996 | 0.985–1.007 | 0.426 |

BMI = body mass index, SELENA-SLEDAI = safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index, SDI = Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index, HR = hazard ratio, CI = confidence interval.
associated with cardiac involvement. The cumulative incidence rates of cardiac involvement for men, anti-Sm antibody positivity, and SDI ≥ 1 over time were analyzed using Kaplan-Meier curves (14.056, 95% CI, 4.271–46.259, \( P < 0.001 \); 3.173, 95% CI, 1.016–9.910, \( P = 0.036 \); 9.609, 95% CI, 2.599–35.527, \( P < 0.001 \), respectively) (Fig. 1).

**DISCUSSION**

It is recognized that patients with SLE have lower life expectancies than the general population.\(^{17,18}\) Infection, malignancy, renal diseases, and CVD are considered major causes of mortality in SLE patients. Over decades, several studies have focused on causes or risk factors of CVD in SLE. In addition to traditional risk factors identified in the general population, several lupus-specific factors were found to be associated with the onset of CVD in patients with SLE.\(^{10,12}\) However, the results of these studies were somewhat heterogeneous depending on the characteristics of the study population. Here, we determined whether traditional and disease-specific risk factors are related to the development of vascular and non-vascular cardiac involvement including angina pectoris, myocardial infarction, cardiomyopathy, valvular heart disease, and pericarditis over a median follow-up period of about 47.6 months. We observed that factors such as men, older age, positive anti-Sm antibody, SDI, and corticosteroid use at baseline were associated with increased risk of cardiac involvement in SLE.

Increasing evidence indicates that lupus-related autoantibodies might be involved in atherosclerosis in cardiovascular events, including ischemic heart disease and stroke in SLE. There are few studies of the relationships between cardiac involvement and lupus-specific antibodies. Considering the role of anti-dsDNA antibody as a lupus-specific biomarker related to disease activity, its positivity was significantly associated with premature atherosclerosis manifesting as coronary plaque in patients with SLE (\( P = 0.032 \)).\(^{19}\) In contrast, we did not detect an association between the presence of anti-dsDNA antibody at baseline and development of cardiac involvement (\( P = 0.137 \)). In general, there is evidence that anti-phospholipid antibodies contribute to endothelial dysfunction through induction of vascular inflammation and apoptosis and are associated with the development of CVD in SLE. The LUMINA cohort study found that any antiphospholipid antibody at baseline predicted occurrence of vascular events during a median follow-up duration of 73.8 months (HR, 3.463, \( P = 0.007 \)).\(^{20}\) Similarly, Gustafsson et al.\(^{21}\) demonstrated an independent predictor
of antiphospholipid antibodies including anti-cardiolipin antibody IgG and anti-β2GP1 IgG for cardiovascular events (HR, 2.57, \(P = 0.02\); HR, 2.57, \(P = 0.02\), respectively). In contrast, there were no differences of non-vascular cardiac involvement including left ventricular mass, left ventricular hypertrophy or ejection fraction between patients with and without antiphospholipid antibody.\(^{22}\) In our study, we failed to demonstrate significant differences in frequencies of anti-phospholipid antibodies between patients with and without cardiac involvement. In other words, we observed that patients with anti-Sm antibody were at increased risk of CVD compared to those without anti-Sm antibody (HR, 17.746; \(P = 0.008\)). However, most studies found no association between anti-Sm antibody and the risk of CVD in SLE.\(^{21,23}\) Although the roles of autoantibodies in previous studies were lack of consistency, it suggests that some lupus-related autoantibodies play crucial roles in the development of cardiac involvement through activation of inflammation and autoimmunity. Further research on this relationship between anti-Sm antibody and cardiac involvement needs to be verified.

It has been recognized that the risk of developing cardiac involvement may increase if tissue or organ damage in patients with SLE is present during disease course. SDI, a representative tool that measures cumulative damage during the course of SLE, was found to be predictive of deleterious outcomes such as hospitalization and death in SLE patients.\(^{24}\) In an analysis of 442 SLE patients in the LUMINA cohort, SDI was associated with vascular arterial events including angina pectoris, myocardial infarction, and stroke (odds ratio [OR], 1.271, 95% CI, 1.134–1.425, \(P < 0.001\)).\(^{25}\) In a multicenter retrospective case-control study, patients with at least one SDI tended to have CVD in univariate analysis, although statistical significance was lost after adjustments for age and gender.\(^{23}\) However, hazard model analysis in our study revealed that the presence of at least one damage score (SDI ≥ 1) increased risk of cardiac involvement after adjustments for confounding factors (HR, 6.444, \(P = 0.042\)). It will be necessary to confirm whether lupus-related tissue or organ damage predicts the risk of cardiac involvement in a larger study population.

Consistent with findings in the general population, traditional risk factors such as obesity, older age, hypertension, dyslipidemia, and diabetes mellitus remain crucial to the development of CVD in SLE.\(^{10,12}\) Considering the effect of gender on cardiovascular involvement, evidence that men are at elevated risk for the development of CVD has previously been addressed. In an analysis of 1979 patients in the Hopkins Lupus Cohort, men patients had more frequent CVD such as angina, myocardial infarction, and left ventricular hypertrophy than women based on SDI.\(^{26}\) Stefanidou et al.\(^{27}\) reported that men had higher prevalence of vascular thrombosis and stroke compared to women SLE patients (OR, 5.832, \(P < 0.001\); OR = 12.289, \(P < 0.001\), respectively). The GLADEL cohort showed that there were no differences in cardiovascular events between men and women SLE patients at the onset of disease, but cumulative incidence increased in men during the course of disease.\(^{28}\) Consistently, we also found that men lupus patients had greater than 18-fold increased risk of cardiac involvement. However, a systemic review and meta-analysis of a total 11,934 SLE patients across 16 studies recently demonstrated that there were no significant differences of CVD and pericarditis between men and women (OR,1.43, 95% CI, 0.93–2.19; OR, 1.19, 95% CI, 0.97–1.45).\(^{29}\) Cardiovascular events including myocardial infarction and valvular heart disease did not differ between genders based on SDI in a retrospective analysis of Korean SLE patients at a single tertiary hospital.\(^{30}\) In another aspect, older age has consistently been regarded as a potent risk factor for CVD. Gustafsson et al.\(^{24}\) demonstrated that age at baseline predicted approximately 2.4-fold increased risk of cardiovascular events such as ischemic heart disease, cerebrovascular or peripheral vascular disease and death. Another
study revealed that age at study entry was significantly associated with cardiovascular events in SLE.\textsuperscript{5} We also confirmed that age at baseline was an independent risk factor for cardiac involvement. Whether traditional risk factors such as gender and age have unfavorable effects on cardiac involvement should be identified in further studies.

There is evidence that therapeutic medications for SLE may be independent risk factors for the development of CVD. Corticosteroids are known to have beneficial effects against SLE by blocking inflammation and reducing organ damage.\textsuperscript{12} This can be an expected preventive effect of corticosteroid on the occurrence of CVD. In contrast, high dose and long-term steroid use were found to increase risk of CVD through the induction of hypertension, hyperlipidemia, and insulin resistance.\textsuperscript{10,12} In this study, we found that corticosteroid use increased the risk of cardiac involvement after adjusting for confounding factors in Cox proportional hazard model analysis (HR, 1.112, \textit{P} = 0.047). Hydroxychloroquine, commonly used in SLE, is protective against risk of cardiovascular events including myocardial infarction, angina, and stroke through favorable effects on lipid profiles and glucose control.\textsuperscript{31} However, in our study we did not observe lower risk of cardiac involvement in patients who used hydroxychloroquine compared to those who did not, similar to other earlier studies.\textsuperscript{21,23} There is still a debate about the effect of medications on cardiovascular events, further consideration is needed through future prospective studies.

There are some limitations in understanding the results of this study. First, this study was to identify new development of vascular and non-vascular cardiac events during a mean follow-up of 47.6 months or more in SLE patients who had no cardiac diseases at the beginning of enrollment. Cumulative incidence of cardiac diseases was only 2.7\%, which is likely to be lower than the rate shown in previous cohort study for patients with cutaneous lupus erythematosus.\textsuperscript{32} In Korean lupus patients for six-year follow-up, the incidence rates of myocardial infarction and heart failure were about 1.76 and 3.11, respectively.\textsuperscript{13} It is considered to be similar to or slightly higher than our results, and is partly consistent with this study. Second, the number of patients enrolled in this study seems to be too small to fully reflect our finding in actual clinical practice. However, the data collection and management of our study are relatively well-designed. Therefore, it can overcome this weakness to some extent.

In conclusion, the novel finding of this study is that disease-specific factors such as anti-Sm antibody, SDI, and corticosteroid use are associated with increased risk of vascular and non-vascular cardiac involvement including angina pectoris, myocardial infarction, cardiomyopathy, valvular heart disease, and pericarditis in Korean patients with SLE, in addition to traditional factors including men gender and older age. Earlier studies reported that disease activity indexes such as SLEDAI or Systemic Lupus Activity Measure predict the risk of developing CVD.\textsuperscript{5,25} However, we failed to identify a predictive role for disease activity indexes such as SELENA-SLEDAI and complements for the risk of the development of cardiac involvement. The results of this study provide a clinically meaningful evidence for the prevention and management of cardiac involvement in patients with SLE. In order to prevent and manage cardiac diseases in patients with SLE, physical examination, laboratory tests on autoantibodies, and presence of tissues and organ damage need to be carried out periodically, and if possible, efforts to reduce the use of steroids are considered.
ACKNOWLEDGMENTS

Electronic development of the case report form and data management for this study were performed using internet-based Clinical Research and Trial management system (iCReaT; http://icreat.nih.go.kr/cdc/webapps/com/hismainweb/jsp/cdc_n2.live), a data management system established by the Centers for Disease Control and Prevention, Ministry of Health and Welfare, Republic of Korea (iCReaT Study No. C140018). The editing service for this manuscript was provided by eWorldEditing, Inc. (Eugene, OR, USA).

REFERENCES

1. Lisnevskaya L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014;384(9957):1878-88.
   PUBMED | CROSSREF
2. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365(22):2110-21.
   PUBMED | CROSSREF
3. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 2004;3(6):423-53.
   PUBMED | CROSSREF
4. Aviña-Zubieta JA, To F, Vostretsova K, De Vera M, Sayre EC, Esdaile JM. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study. Arthritis Care Res (Hoboken) 2017;69(6):849-56.
   PUBMED | CROSSREF
5. Tsilios K, Gladman DD, Su J, Ace O, Urowitz MB. Evolution of risk factors for atherosclerotic cardiovascular events in systemic lupus erythematosus: a longterm prospective study. J Rheumatol 2017;44(12):1841-9.
   PUBMED | CROSSREF
6. Kim SK, Choe JY, Lee SS. Self-reported physical activity is associated with lupus nephritis in systemic lupus erythematosus: data from KORean Lupus Network (KORNET) registry. Yonsei Med J 2018;59(7):857-64.
   PUBMED | CROSSREF
7. Koh JH, Park EK, Lee HN, Kim Y, Kim GT, Suh YS, et al. Clinical characteristics and survival of 413 patients with systemic lupus erythematosus in southeastern areas of South Korea: a multicenter retrospective cohort study. Int J Rheum Dis 2020;23(1):92-100.
   PUBMED | CROSSREF
8. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93(3):513-9.
   PUBMED | CROSSREF
9. Urowitz MB, Ibáñez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007;34(1):70-5.
   PUBMED
10. Sinicato NA, da Silva Cardoso PA, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev 2013;9(1):15-9.
   PUBMED
11. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145(5):408-15.
   PUBMED | CROSSREF
12. Teixeira V, Tami LS. Novel insights in systemic lupus erythematosus and atherosclerosis. Front Med (Lausanne) 2018;5:262.
   PUBMED | CROSSREF
13. Lim SY, Bae EH, Han KD, Jung JH, Choi HS, Kim HY, et al. Systemic lupus erythematosus is a risk factor for cardiovascular disease: a nationwide, population-based study in Korea. Lupus 2018;27(13):2050-6.
   PUBMED | CROSSREF
14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25(11):1271-7.
   PUBMED | CROSSREF
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40(9):1725. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/9434687) | [CROSSREF](https://doi.org/10.1002/art.1780400906)

16. Steering Committee. The Asia-Pacific perspective: Redefining Obesity and Its Treatment. Melbourne: International Diabetes Institute; 2000.

17. Rees F, Doherty M, Grainge MJ, Lanyon P, Davenport G, Zhang W. Mortality in systemic lupus erythematosus in the United Kingdom 1999–2012. *Rheumatology (Oxford)* 2016;55(5):854-60. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/26903213) | [CROSSREF](https://doi.org/10.1093/rdp/rwp198)

18. Yee CS, Su L, Toescu V, Hickman R, Situnayake D, Bowman S, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. *Rheumatology (Oxford)* 2015;54(8):836-43. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/26035385) | [CROSSREF](https://doi.org/10.1093/rheumatology/keu252)

19. Kiani AN, Vogel-Claussen J, Arbab-Zadeh A, Magder LS, Lima J, Petri M. Semiquantified noncalcified coronary plaque in systemic lupus erythematosus. *J Rheumatol* 2012;39(12):2286-93. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/23008657) | [CROSSREF](https://doi.org/10.3899/jrheum.120016)

20. Toloza SM, Uribe AG, McGwinn G Jr, Alarcón GS, Fessler BJ, Bastian HM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. *Arthritis Rheum* 2004;50(12):3947-57. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/15567246) | [CROSSREF](https://doi.org/10.1002/art.1610501211)

21. Gustafsson J, Gunnarsson I, Börjesson O, Pettersson S, Möller S, Fei GZ, et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. *Arthritis Res Ther* 2009;11(6):R186. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/19614802) | [CROSSREF](https://doi.org/10.1186/ar2642)

22. Lockshin M, Tenedios F, Petri M, McCarty G, Forastiero R, Krikis S, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. *Lupus* 2003;12(7):518-23. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/14549751) | [CROSSREF](https://doi.org/10.12968/lupus.2003.12.7.518)

23. Haque S, Gordon C, Isenberg D, Rahman A, Lanyon P, Bell A, et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. *J Rheumatol* 2010;37(2):322-9. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/20062908) | [CROSSREF](https://doi.org/10.3899/jrheum.100038)

24. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. *Lupus* 2001;10(2):93-6. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/11174891) | [CROSSREF](https://doi.org/10.1002/1529-8021(200103)10:2<93::AID-LUPUS9>3.0.CO;2-9)

25. Ho KT, Ahn CW, Alarcón GS, Baethge BA, Tan FK, Roseman J, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. *Rheumatology (Oxford)* 2005;44(10):1303-7. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/15949135) | [CROSSREF](https://doi.org/10.1093/rheumatology/keh084)

26. Tan TC, Fang H, Magder LS, Petri MA. Differences between male and female systemic lupus erythematosus in a multiethnic population. *J Rheumatol* 2012;39(4):759-69. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/22635164) | [CROSSREF](https://doi.org/10.3899/jrheum.110619)

27. Stefanidou S, Benos A, Galanopoulou V, Chatziyannis I, Kanakoudi F, Aslanidis S, et al. Clinical expression and morbidity of systemic lupus erythematosus during a post-diagnostic 5-year follow-up: a male:female comparison. *Lupus* 2011;20(10):1090-4. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/21279920) | [CROSSREF](https://doi.org/10.1177/0961203311402221)

28. Garcia MA, Marcos JC, Marcos AI, Pons-Estel BA, Wójcyla D, Arturi A, et al. Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients. *Lupus* 2005;14(12):938-46. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/16069755) | [CROSSREF](https://doi.org/10.1177/096120330501401201)

29. Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: a systematic review and meta-analysis. *Medicine (Baltimore)* 2016;95(29):e4272. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/27824991) | [CROSSREF](https://doi.org/10.1097/MD.0000000000003457)

30. Hwang J, Lee J, Ahn JK, Park EJ, Cha HS, Koh EM. Clinical characteristics of male and female Korean patients with systemic lupus erythematosus: a comparative study. *Korean J Intern Med* 2015;30(2):242-9. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/25682923) | [CROSSREF](https://doi.org/10.3904/kjim.2015.30.2.242)

31. Penn SK, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. *J Rheumatol* 2010;37(6):1136-42. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/20161228) | [CROSSREF](https://doi.org/10.3899/jrheum.090892)

32. Singh AG, Crowson CS, Singh S, Denis M, Davis P, Maradit-Kremers H, et al. Risk of cerebrovascular accidents and ischemic heart disease in cutaneous lupus erythematosus: a population-based cohort study. *Arthritis Care Res (Hoboken)* 2016;68(11):1664-70. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/27332360) | [CROSSREF](https://doi.org/10.1002acr.23069)